Core Viewpoint - The shareholder Advanced Manufacturing Industry Investment Fund plans to reduce its stake in He Eye Hospital by selling up to 3.106074 million shares, representing 1.97% of the total share capital [1] Group 1 - The planned reduction will occur from February 7, 2026, to May 6, 2026 [1] - The share reduction will be executed through centralized bidding and block trading on the stock exchange [1] - The percentage of shares being sold accounts for 2% of the total share capital after excluding shares held in the repurchase special securities account [1]

Core Viewpoint - The company, He Shi Eye Hospital (301103.SZ), announced that its shareholder, Advanced Manufacturing Industry Investment Fund (Limited Partnership), plans to reduce its shareholding by up to 3.106074 million shares, representing 1.97% of the total share capital of the company [1] Summary by Relevant Categories Shareholder Actions - The Advanced Manufacturing Industry Investment Fund intends to reduce its holdings from February 7, 2026, to May 6, 2026, through centralized bidding and block trading on the stock exchange [1] - The planned reduction accounts for 2% of the total share capital after excluding shares held in the repurchase special securities account [1]

Core Viewpoint - Advanced Manufacturing Industry Investment Fund plans to reduce its stake in He Eye Hospital by up to 3.1061 million shares, representing 1.97% of the total share capital, due to the shareholder's personal funding needs [1] Group 1: Shareholder Information - Advanced Manufacturing Fund currently holds 10.3299 million shares, accounting for 6.54% of the total share capital [1] - After excluding repurchased shares, the fund's stake is 6.65% of the adjusted total share capital [1] Group 2: Reduction Plan Details - The reduction will occur within three months, starting fifteen trading days after the announcement [1] - The shares will be sold through centralized bidding and block trading on the stock exchange [1]

Group 1 - The core point of the article is that He Eye Hospital Group announced a share reduction plan by a major shareholder, which will take place over a specified period [1] - The shareholder, Advanced Manufacturing Industry Investment Fund, plans to reduce its holdings by up to approximately 3.11 million shares, representing 1.97% of the company's total share capital [1] - The reduction period is set from February 7, 2026, to May 6, 2026, and the number of shares to be reduced may be adjusted in case of any corporate actions such as dividends or stock splits [1]

何氏眼科公告称，近日收到持股5%以上股东先进制造基金的减持告知函。其计划自公告披露之日起十 五个交易日后的三个月内（2026年2月7日至5月6日），通过集中竞价和大宗交易方式减持不超310.61万 股，占公司总股本的1.97%（占剔除回购专用证券账户中股份数量后总股本的2%）。先进制造基金目前 持股1032.99万股，占公司总股本的6.54%，减持原因为自身资金需求。 ...

（来源：邯郸日报） 转自：邯郸日报 本报讯（记者张君）近日，邯郸市眼科医院从全国眼外伤登记工作评选中脱颖而出，获得中华医学会眼 科学分会眼外伤学组颁发的"中国眼外伤登记工作优秀奖"。 眼外伤作为高致盲性眼科急症，规范的诊疗数据收集是优化救治方案、完善预防体系的关键。自参与全 国眼外伤登记工作以来，该院眼外伤科梁娜团队秉持"精准、规范、高效"原则，建立覆盖急诊接诊、手 术治疗、术后随访的全流程数据采集体系，克服临床工作压力，确保每一例病例信息真实完整、上报及 时准确，为全国眼外伤流行病学研究和诊疗指南优化提供了宝贵的地方实践数据。 作为区域内唯一公立眼外伤专业救治医院，市眼科医院眼外伤科开通24小时急诊绿色通道，在复杂眼外 伤急诊处理与手术治疗方面经验丰富。此次获奖彰显了医院"临床与科研并重、质量与规范同行"的发展 理念。该院将以此次获奖为契机，持续优化登记工作流程，深化数据应用与科研转化，进一步提升眼外 伤诊疗精准化、规范化水平，为守护区域群众眼健康、推动眼外伤防治事业发展注入更强动力。 ...

Core Viewpoint - A-share listed companies are actively engaging in shareholder return activities, utilizing methods beyond cash dividends, such as offering products, services, discount coupons, or exclusive rights, with mixed market performance but overall outpacing the CSI 300 index [1] Group 1: Shareholder Return Activities - Approximately 130 companies have shown varied market performance, with some adopting creative ways to reward shareholders [1] - Companies are not only providing gifts but are also formulating future dividend plans, with 10 companies announcing shareholder return strategies for the next three years [1] Group 2: Dividend Plans and Performance - The top performers in terms of stock price increase since 2025 include Haoen Qidian (301488) with a rise of 205.66%, Shuiyang Co. (300740) at 87.59%, and Huasheng Co. (600156) at 69.18% [3] - Specific dividend plans include: - Haoen Qidian: Minimum 10% of distributable profit annually from 2025 to 2027 [3] - Shuiyang Co.: Cash dividends not less than 10% of distributable profit annually from 2025 to 2027 [3] - Huasheng Co.: Cumulative cash distribution of at least 30% of the average distributable profit over the last three years from 2026 to 2028 [3] - Other companies like Gais Food (36.36%) and Bona Film (34.26%) also have significant dividend commitments [3]

Core Viewpoint - He Eye Hospital is focusing on the strategic goal of "Smart Bright City" by building an "Internet + Healthcare" full lifecycle eye health management platform [2] Group 1: Business Development - The company has integrated intelligent diagnostic systems and established an intelligent imaging cloud platform for ophthalmology [2] - He Eye Hospital has developed a multimodal data fusion decision-making system leveraging deep learning algorithms for health management [2] Group 2: Product Innovations - The "He Diabetes Manager" combines dynamic blood glucose monitoring devices to provide real-time blood sugar level monitoring, enabling precise blood sugar control and eye disease prevention for diabetes patients [2] - The "Bright House" utilizes smart ophthalmic equipment as an entry point, integrating online and offline diagnosis and treatment systems to screen for eye diseases and related chronic conditions [2] Group 3: Impact on Business Performance - Currently, these initiatives have not significantly impacted the company's main business and performance, but the company will fulfill information disclosure obligations if there are major developments [2]

Core Viewpoint - The company emphasizes that its stock price is influenced by multiple market factors and is committed to monitoring stock price fluctuations while prioritizing investor returns [1] Group 1 - The company stated that if it triggers the conditions for disclosing performance forecasts, it will disclose them within one month after the end of the accounting year [1] - If the conditions are not triggered, the company is not required to disclose performance forecasts [1] - Investors are advised to refer to the announcements published in the company's designated information disclosure media for relevant information [1]

Core Viewpoint - Jiangsu Taixue Eye Hospital Co., Ltd. has been established with a registered capital of 50 million RMB, fully owned by Taixue (Shanghai) Medical Equipment Trading Co., Ltd. [1] Group 1: Company Information - The legal representative of Jiangsu Taixue Eye Hospital is Fang Weixiang [1] - The registered capital of the company is 50 million RMB [1] - The company is classified as a limited liability company (wholly foreign-owned enterprise) [1] Group 2: Shareholding Structure - Taixue (Shanghai) Medical Equipment Trading Co., Ltd. holds 100% of the shares [1] Group 3: Business Scope - The business scope includes medical services, drug retail, third-class medical device operations, internet information services for medical devices, and food sales [1] - Other services include nursing institution services (excluding medical services), sales of second-class and first-class medical devices, cosmetics retail, daily necessities sales, and electronic products sales [1] - The company also engages in technical services, enterprise management consulting, health consulting services (excluding diagnosis and treatment services), and investment activities with its own funds [1]